In a letter urging the agency to reject the drug . . .

FDA Committee Chair Bucks Panel's Support Of Sufentanil Tablet

October 23, 2018
The head of FDA's anesthetic and analgesic advisory committee has joined consumer group Public Citizen in urging FDA to reject approval of AcelRx's DSUVIA, a sufentanil sublingual drug-device combination tablet that is five to 10 times more potent than fentanyl. In a letter sent to FDA officials Thursday (Oct. 18), the committee head argues FDA would not be able to enforce risk controls for DSUVIA and predicts that, if approved, the drug would lead to diversion, abuse and death within...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.